Enlivex Therapeutics Ltd. (ENLV) Stock
Healthcare · Biotechnology · IL
$0.77
-19.64%
Last updated Jun 19, 2026 00:03 UTC
ENLV Key Statistics
Market Cap$18.78M
P/E (TTM)0.03
P/S (TTM)—
P/B (TTM)0.02
Revenue (TTM)$0.00
EPS (TTM)$25.46
Dividend Yield—
ROE (TTM)248.08%
Net Margin0.00%
Gross Margin0.00%
52W High$1.32
52W Low$0.75
Analyst ViewBuy
Price Target$15.00
Employees71
Volume899,273
About Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
CEO: Oren Hershkovitz. Company website
See ENLV live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ENLV in Terminal See plans